In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Lixisenatide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 768 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 164 (163 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 67 · 5 active9 more mention it but do not test it | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Adlyxin says: “Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Lixisenatide | Semaglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 35334571 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
| Body weightMetabolic and weight | 3333 | 969954105 |
|---|
| Adverse eventsWhole body | 117117 | 7757723 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 3838 | 345345 |
|---|
| Cardiovascular eventsCardiovascular | 321 | 2672634 |
|---|
| Kidney functionKidney and urinary | 25241 | 1361351 |
|---|
| LipidsMetabolic and weight | 99 | 1181171 |
|---|
| Blood pressureCardiovascular | 981 | 9999 |
|---|
| MortalityWhole body | 22 | 1041031 |
|---|
| Appetite and food intakeMetabolic and weight | 1091 | 97952 |
|---|
| PharmacokineticsPharmacology | 13112 | 93894 |
|---|
| Exercise and physical functionNervous system and cognition | 33 | 6969 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Lixisenatide differs from Exenatide at 7 positions.
What is different
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Lixisenatide | Semaglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −0.4% Placebo-corrected HbA1c change from baseline Dose studied: 20 μg24 weeksn = 4952013 | −1.6 to −0.4% Estimated treatment difference Dose studied: 2.5-40 mg once daily26 weeksn not reported2017 |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | −1.12 kg Body weight change · lixisenatide, week 24 Placebo, week 24: 0.04 kg 24 weeksn = 4482018 | −14.2 kg body weight change |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 50% Gastrointestinal events · lixisenatide, through week 52 52 weeksn = 3212020 | 41.8% Gastrointestinal adverse events |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 63.8% Treatment-emergent adverse events Placebo: 40.8% 24 weeksn = 4482018 | 86.2% Adverse events · semaglutide 0.5 mg |
−0.4%
Placebo-corrected HbA1c change from baseline
Dose studied: 20 μg24 weeksn = 4952013
−1.6 to −0.4%
Estimated treatment difference
Dose studied: 2.5-40 mg once daily26 weeksn not reported2017
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Lixisenatide | Semaglutide |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 6.5% primary end-point event rate Placebo: 8% Dose studied: 2.4 mg once weeklyn = 17,604 |
Placebo: −3.3 kg
Dose studied: 2.4 mg once a week48 weeksn not reported2026
Dose studied: 1.0 mg once weekly56 weeksn = 8132018
−1.12 kg
Body weight change · lixisenatide, week 24
Placebo, week 24: 0.04 kg
24 weeksn = 4482018
−14.2 kg
body weight change · semaglutide 2.4 mg
Placebo: −3.3 kg
Dose studied: 2.4 mg once a week48 weeksn not reported2026
50%
Gastrointestinal events · lixisenatide, through week 52
52 weeksn = 3212020
41.8%
Gastrointestinal adverse events
Dose studied: 1.0 mg once weekly56 weeksn = 8132018
63.8%
Treatment-emergent adverse events
Placebo: 40.8%
24 weeksn = 4482018
86.2%
Adverse events · semaglutide 0.5 mg
Dose studied: 0.5 mg56 weeksn = 6012018
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No comparable result 7 randomized-trial results measure it in another way or another unit. | −3.84 mm Hg SBP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| LipidsMetabolic and weightCompared as: difference from placebo, in % | No comparable result 5 randomized-trial results measure it in another way or another unit. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Exercise and physical functionCardiovascularCompared as: difference from placebo, in points | No comparable result 3 randomized-trial results measure it in another way or another unit. | 7.3 points estimated difference Dose studied: 2.4 mg once weekly52 weeksn = 6162024 |
|---|
| Patterns of useMetabolic and weightCompared as: value in the arm that got the peptide, in u | −3 U Change in daily basal insulin dose · lixisenatide, week 24 Placebo, week 24: −1.9 U 24 weeksn = 4482018 | No comparable result 8 randomized-trial results measure it in another way or another unit. |
|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No comparable result 19 randomized-trial results measure it in another way or another unit. | −52.1% UACR change Dose studied: 2.4 mg per week24 weeksn = 1012025 |
|---|
| Vascular functionCardiovascularCompared as: difference from placebo, in p-value | 0.38 p-value Between-group p value for Ao-PWV 24 weeksn = 902026 | No comparable result 4 randomized-trial results measure it in another way or another unit. |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 8% Paracetamol AUC0-5h increase Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021 |
|---|
No comparable result
2 randomized-trial results measure it in another way or another unit.
6.5%
primary end-point event rate
Placebo: 8%
Dose studied: 2.4 mg once weeklyn = 17,6042023
No comparable result
7 randomized-trial results measure it in another way or another unit.
−3.84 mm Hg
SBP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No comparable result
5 randomized-trial results measure it in another way or another unit.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No comparable result
3 randomized-trial results measure it in another way or another unit.
7.3 points
estimated difference
Dose studied: 2.4 mg once weekly52 weeksn = 6162024
−3 U
Change in daily basal insulin dose · lixisenatide, week 24
Placebo, week 24: −1.9 U
24 weeksn = 4482018
No comparable result
8 randomized-trial results measure it in another way or another unit.
No comparable result
19 randomized-trial results measure it in another way or another unit.
−52.1%
UACR change
Dose studied: 2.4 mg per week24 weeksn = 1012025
0.38 p-value
Between-group p value for Ao-PWV
24 weeksn = 902026
No comparable result
4 randomized-trial results measure it in another way or another unit.
No comparable result
2 randomized-trial results measure it in another way or another unit.
8%
Paracetamol AUC0-5h increase
Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 67 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Sanofi6,068 participantsJun 2010 to Feb 2015
Acute Coronary Syndrome
Sanofi1,170 participantsFeb 2014 to Jun 2015
Type 2 Diabetes
Sanofi894 participantsJan 2013 to Dec 2014
Type 2 Diabetes
9 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.